We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Illumina, Inc.’s (ILMN - Free Report) market opportunities continue to expand owing to accelerated demand from clinical and translational customers. However, government budget cuts, including NIH funding issues, and competition act as major downsides.
In the past six months, Illumina has outperformed its industry. The stock has gained 22.9% against the industry's decline of 8%. Illumina exited the first quarter of 2021 with better-than-expected results. Gradually improving business conditions buoy optimism on the stock. Sequential improvement in segmental revenues across most geographies looks impressive as well. Strong microarrays revenues are also encouraging.
Additionally, robust adoption of NovaSeq 6000 v1.5 reagents to enhance deeper genomic discoveries is a positive. Receipt of the medical device registration in Russia for NextSeq 550Dx and its associated reagent kits are also praiseworthy. The announcement of TSO 500 partnership with Kartos Therapeutics to advance comprehensive genomic profiling (CGP) for blood cancers augurs well for the stock.
In the first quarter, Illumina derived benefits from the cascading effect of the ACOG guidance on increasing coverage of NIPT for all pregnancies. This led the company’s reproductive health business to register the third consecutive quarter of both year-over-year and sequential growth. Illumina, in partnership with Harvard Pilgrim Health Care, published favorable economic study results in March. This study demonstrated the cost-effectiveness of offering NIPT to pregnant women.
Internationally, the adoption of the CE-IVD-marked NIPT kit has been robust, reflecting increasing NIPT coverage.
Earlier the company noted that with multiple large payors expanding coverage for all pregnancies, the company expects NIPT coverage in the United States to exceed three million pregnancies by the end of 2021.
Solid long-term growth potential in the oncology space and worldwide expansion to drive growth also buoy optimism. A strong capital structure is an added plus.
On the flip side, pandemic-led lower sequencing revenues remain a concern. Contraction in both margins does not bode well either. Government budget cuts, including NIH funding issues, and competition are major downsides.
Zacks Rank and Key Picks
Illumina currently carries a Zacks Rank #3 (Hold).
Envista Holdings has an estimated long-term earnings growth rate of 26%.
Phibro Animal Health has an estimated long-term earnings growth rate of 11%.
IDEXX Laboratories has a projected long-term earnings growth rate of 20%.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
Illumina's (ILMN) NovaSeq Adoption Aids, Margin Woe Stays
Illumina, Inc.’s (ILMN - Free Report) market opportunities continue to expand owing to accelerated demand from clinical and translational customers. However, government budget cuts, including NIH funding issues, and competition act as major downsides.
In the past six months, Illumina has outperformed its industry. The stock has gained 22.9% against the industry's decline of 8%. Illumina exited the first quarter of 2021 with better-than-expected results. Gradually improving business conditions buoy optimism on the stock. Sequential improvement in segmental revenues across most geographies looks impressive as well. Strong microarrays revenues are also encouraging.
Additionally, robust adoption of NovaSeq 6000 v1.5 reagents to enhance deeper genomic discoveries is a positive. Receipt of the medical device registration in Russia for NextSeq 550Dx and its associated reagent kits are also praiseworthy. The announcement of TSO 500 partnership with Kartos Therapeutics to advance comprehensive genomic profiling (CGP) for blood cancers augurs well for the stock.
In the first quarter, Illumina derived benefits from the cascading effect of the ACOG guidance on increasing coverage of NIPT for all pregnancies. This led the company’s reproductive health business to register the third consecutive quarter of both year-over-year and sequential growth. Illumina, in partnership with Harvard Pilgrim Health Care, published favorable economic study results in March. This study demonstrated the cost-effectiveness of offering NIPT to pregnant women.
Illumina, Inc. Price
Illumina, Inc. price | Illumina, Inc. Quote
Internationally, the adoption of the CE-IVD-marked NIPT kit has been robust, reflecting increasing NIPT coverage.
Earlier the company noted that with multiple large payors expanding coverage for all pregnancies, the company expects NIPT coverage in the United States to exceed three million pregnancies by the end of 2021.
Solid long-term growth potential in the oncology space and worldwide expansion to drive growth also buoy optimism. A strong capital structure is an added plus.
On the flip side, pandemic-led lower sequencing revenues remain a concern. Contraction in both margins does not bode well either. Government budget cuts, including NIH funding issues, and competition are major downsides.
Zacks Rank and Key Picks
Illumina currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the broader medical space are Envista Holdings Corporation (NVST - Free Report) , Phibro Animal Health Corporation (PAHC - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) each carrying a Zacks Rank #2 (Buy). You can see the complete list of Zacks #1 Rank (Strong Buy) stocks here.
Envista Holdings has an estimated long-term earnings growth rate of 26%.
Phibro Animal Health has an estimated long-term earnings growth rate of 11%.
IDEXX Laboratories has a projected long-term earnings growth rate of 20%.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>